stockrowNeuronetics, Inc.
STIMNeuronetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $149.2 million, up 99.2% from fiscal 2024.
- Revenue
- +12.5%
- EPS
- +84.5%
- Free cash flow
- +185.4%
- Total debt
- −5.97%
Quarter to September 2026, against a year earlier
Follow STIM
Alert me
Neuronetics, Inc. (STIM) Return on invested capital
Neuronetics, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −16.7%, up 17.3 percentage points from fiscal 2025 (−34.1%). Over the past ten years it has ranged from −697.8% (fiscal 2019) to 0.00% (fiscal 2018); the current reading is higher than 60% of that period. That is below the Medical Devices industry median of −5.35% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −34.1% | (1.95) |
| FY2024 | −32.1% | 25.95 |
| FY2023 | −58.1% | 45.76 |
| FY2022 | −103.8% | (34.47) |
| FY2021 | −69.4% | 72.02 |
| FY2020 | −141.4% | 556.44 |
| FY2019 | −697.8% | (697.81) |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ELMD Electromed, Inc. compare | 25.1% |
| TLSI TriSalus Life Sciences, Inc. compare | 0.00% |
| APYX Apyx Medical Corporation compare | −10.3% |
| STIM Neuronetics, Inc. | −16.7% |
| INGN Inogen, Inc compare | −41.5% |
| MXCT MaxCyte, Inc. compare | −42.4% |
| QTRX Quanterix Corporation compare | −60.8% |
| OWLT Owlet, Inc. compare | −131.0% |
| RXST RxSight, Inc. compare | −16,845.7% |
| Medical Devices industry median | −5.35% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)